Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arcellx
Fierce Pharma
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
The presentation was a comparison between anito-cel’s iMMagine-1 and Carvykti’s Cartitude-1 and -4 trials for the treatment of multiple myeloma.
Angus Liu
Nov 12, 2025 11:36am
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Nov 5, 2024 3:08pm
NIH to invest another $515M over 4 years for long COVID research
Feb 15, 2024 10:57am
Gilead hands Arcellx $285M to expand BCMA cell therapy deal
Nov 15, 2023 10:00am
FDA lifts hold on Gilead's CAR-T as Arcellx sheds light on death
Aug 15, 2023 8:32am
FDA puts Gilead's $225M BCMA CAR-T on hold over patient death
Jun 20, 2023 6:15am